TY - JOUR
T1 - Accelerating drug development through collaboration
T2 - The Hepatitis C drug development advisory group
AU - Hutchison, C.
AU - Kwong, A.
AU - Ray, S.
AU - Struble, K.
AU - Swan, T.
AU - Miller, V.
PY - 2014
Y1 - 2014
N2 - Over the past decade, landmark collaboration between regulatory agencies, pharmaceutical companies, academia, and patient community representatives has enabled the development and approval of new hepatitis C virus (HCV) treatment regimens with unprecedented speed. By providing a neutral platform for cross-sector engagement, the Forum for Collaborative HIV Research's 1 HCV Drug Development Advisory Group played a critical role in fostering this collaboration and expediting drug development. The applicability of this model to other therapeutic areas should be explored.
AB - Over the past decade, landmark collaboration between regulatory agencies, pharmaceutical companies, academia, and patient community representatives has enabled the development and approval of new hepatitis C virus (HCV) treatment regimens with unprecedented speed. By providing a neutral platform for cross-sector engagement, the Forum for Collaborative HIV Research's 1 HCV Drug Development Advisory Group played a critical role in fostering this collaboration and expediting drug development. The applicability of this model to other therapeutic areas should be explored.
UR - http://www.scopus.com/inward/record.url?scp=84904857264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904857264&partnerID=8YFLogxK
U2 - 10.1038/clpt.2014.113
DO - 10.1038/clpt.2014.113
M3 - Article
C2 - 24853733
AN - SCOPUS:84904857264
SN - 0009-9236
VL - 96
SP - 162
EP - 165
JO - Clinical pharmacology and therapeutics
JF - Clinical pharmacology and therapeutics
IS - 2
ER -